BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Julie B. Feder as Chief Financial Officer.
“Julie is an accomplished financial professional with invaluable leadership experience in healthcare, having served as Chief Financial Officer of the Clinton Health Access Initiative and in finance roles of increasing responsibility at Genzyme,” said Robert Forrester, President and Chief Executive Officer of Verastem. “We are delighted to welcome her to our executive team as we look forward to the final data readout of our Phase 3 DUO study evaluating duvelisib in chronic lymphocytic leukemia.”
“I am thrilled to be joining the management team during this exciting time in the company’s growth trajectory,” said Ms. Feder. “Verastem has the potential to become a commercial-stage company with a promising treatment for patients with lymphoid malignancies, and I look forward to working with the leadership team to achieve the company’s financial and strategic objectives.”
Ms. Feder joins Verastem from the Clinton Health Access Initiative, Inc. (CHAI), where she served as Chief Financial Officer for six years. At CHAI, Ms. Feder was responsible for managing a global team across multiple departments, and developed the global finance strategy and internal audit, treasury, and global payroll functions. She also led multiple financial and operational initiatives and was a key member of the CHAI leadership team. Prior to joining CHAI, Ms. Feder spent three years at Genzyme Corporation, first as Vice President of Internal Audit and also as Finance Integration Leader. In these roles, she managed the day-to-day operations of Genzyme’s global internal audit function, while leading the Genzyme Global Finance integration into Sanofi’s organization following Sanofi’s acquisition of Genzyme. Ms. Feder began her career at Deloitte & Touche LLP, where she was Senior Manager of Audit, Consulting and Enterprise Risk Services and served leading organizations in healthcare, including Genzyme Corporation, Children’s Hospital Boston, Dana Farber Cancer Center, Boston Scientific Corporation, and Yale New Haven Hospital. Ms. Feder holds a Bachelor of Science in Accounting from Yeshiva University’s Sy Syms School of Business.
Inducement Equity Awards
In connection with the hiring of Ms. Feder, effective July 10, 2017, Verastem approved a grant to Ms. Feder of a stock option to purchase 370,000 shares of Verastem's common stock. The option was granted pursuant to the NASDAQ inducement grant exception as a component of Ms. Feder’s employment compensation and was granted as an inducement material to her acceptance of employment with Verastem in accordance with NASDAQ Listing Rule 5635(c)(4). The option will have an exercise price equal to $3.45, the closing price of Verastem's common stock on July 10, 2017. The award will vest as to 25% of the shares subject to the option on the first anniversary of the date of hire and as to an additional 6.25% of the shares subject to the option at the end of each successive three-month period following the first anniversary of the date of hire, provided that Ms. Feder continues to serve as an employee of or other service provider to Verastem on each such vesting date.
Verastem also approved grants of stock options to four new employees to purchase an aggregate of 232,500 shares of Verastem’s common stock. The options were granted pursuant to the NASDAQ inducement grant exception as a component of the employees entering into employment with Verastem and were granted as an inducement material to their acceptance of employment with Verastem in accordance with NASDAQ Listing Rule 5635(c)(4). 152,500 options will have an exercise price equal to $3.45, the closing price of Verastem's common stock on July 10, 2017 and 80,000 options will have an exercise price equal to the closing price of Verastem’s common stock on August 10, 2017. The awards will vest as to 25% of the shares subject to the options on the first anniversary of the date of hire and as to an additional 6.25% of the shares subject to the options at the end of each successive three-month period following the first anniversary of the date of hire, provided that the employees continue to serve as an employee of or other service provider to Verastem on each such vesting date.
Duvelisib is an investigational, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells and T-cells. PI3K signaling may lead to the proliferation of malignant B-cells and is thought to play a role in the formation and maintenance of the supportive tumor microenvironment.1,2,3 Duvelisib is currently being evaluated in late- and mid-stage clinical trials, including DUO™, a randomized, Phase 3 monotherapy study in patients with relapsed or refractory CLL,4 and DYNAMO™, a single-arm, Phase 2 monotherapy study in patients with refractory iNHL that achieved its primary endpoint of ORR.5 Duvelisib is also being evaluated for the treatment of hematologic malignancies through investigator-sponsored studies, including T-cell lymphoma.6Information about duvelisib clinical trials can be found on www.clinicaltrials.gov.
About Verastem, Inc.
Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase 3 clinical trial in patients with CLL. In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells. For more information, please visit www.verastem.com.